Magnesium Glycinate Sleep Quality Randomized Trial: What the Evidence Says

Quick Answer

Magnesium Glycinate Sleep Quality Randomized Trial has 1 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• This case series presents outcomes of the first 51 patients who participated in one such program and aims to add to preliminary evidence regarding the efficacy of a personalized multimodal integrative functional medicine approach to cognitive decline in the context of prior uncontrolled and ongoing controlled trials. [Kogan Mikhail (2026); evidence level 4]
• Management of vascular risk factors (hypertension, hyperlipidemia, diabetes), tobacco and alcohol counseling, and hearing evaluation were conducted through participants' primary clinicians, consistent with standard dementia prevention guidelines. [Kogan Mikhail (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For magnesium glycinate sleep quality randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Kogan Mikhail (2026). The Integrative Personalized Functional Medicine Approach to Reverse Cognitive Decline: Academic Experience of the First 51 Patients Case Series. DOI: 10.1177/27536130261452680. PMCID: PMC13219804. PMID: 42221535. License: https://creativecommons.org/licenses/by-nc/4.0/ https://creativecommons.org/licenses/by-nc/4.0/ https://us.sagepub.co.... https://pmc.ncbi.nlm.nih.gov/articles/PMC13219804/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.